Comera Life Sciences Holdings Past Earnings Performance
Past criteria checks 0/6
Comera Life Sciences Holdings's earnings have been declining at an average annual rate of -36%, while the Biotechs industry saw earnings growing at 13% annually. Revenues have been growing at an average rate of 45.2% per year.
Key information
-36.0%
Earnings growth rate
40.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 45.2% |
| Return on equity | -8,809.8% |
| Net Margin | -935.0% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Comera Life Sciences rises on positive preclinical data from Sequrus study
Oct 18Comera life sciences expands woburn operations
Oct 04Comera Life Sciences announces up to $15M purchase agreement with Arena
Aug 31Comera Life Sciences GAAP EPS of -$1.14, revenue of $0.15M
Aug 10Comera Life Sciences Holdings (NASDAQ:CMRA) Is In A Good Position To Deliver On Growth Plans
May 27
Revenue & Expenses BreakdownBeta
How Comera Life Sciences Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 1 | -9 | 7 | 1 |
| 30 Jun 23 | 1 | -10 | 8 | 1 |
| 31 Mar 23 | 1 | -18 | 10 | 1 |
| 31 Dec 22 | 1 | -18 | 9 | 2 |
| 30 Sep 22 | 1 | -17 | 10 | 2 |
| 30 Jun 22 | 0 | -15 | 8 | 1 |
| 31 Mar 22 | 0 | -8 | 6 | 2 |
| 31 Dec 21 | 0 | -5 | 4 | 2 |
| 31 Dec 20 | 0 | -2 | 1 | 1 |
Quality Earnings: CMRA is currently unprofitable.
Growing Profit Margin: CMRA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CMRA's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CMRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CMRA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: CMRA has a negative Return on Equity (-8809.78%), as it is currently unprofitable.